Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
ARDT vs DBVT vs HCA vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
ARDT vs DBVT vs HCA vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology |
| Market Cap | $1.41B | $1712.35T | $95.95B | $5.90B |
| Revenue (TTM) | $6.43B | $0.00 | $75.60B | $1.56B |
| Net Income (TTM) | $134M | $-168M | $6.78B | $153M |
| Gross Margin | 60.5% | — | 41.5% | 65.4% |
| Operating Margin | 8.9% | — | 15.8% | 12.3% |
| Forward P/E | 8.7x | — | 14.2x | 24.8x |
| Total Debt | $2.26B | $22M | $50.20B | $70M |
| Cash & Equiv. | $710M | $194M | $1.04B | $1.12B |
ARDT vs DBVT vs HCA vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Ardent Health Partn… (ARDT) | 100 | 55.3 | -44.7% |
| DBV Technologies S.… (DBVT) | 100 | 330.4 | +230.4% |
| HCA Healthcare, Inc. (HCA) | 100 | 118.2 | +18.2% |
| Alkermes plc (ALKS) | 100 | 129.6 | +29.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARDT vs DBVT vs HCA vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARDT is the #2 pick in this set and the best alternative if value is your priority.
- Lower P/E (8.7x vs 24.8x)
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs ARDT's -30.5%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Rev growth 7.1%, EPS growth 29.0%, 3Y rev CAGR 7.9%
- 450.5% 10Y total return vs ALKS's -11.0%
- 7.1% revenue growth vs DBVT's -100.0%
ALKS is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs DBVT's 0.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.1% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (8.7x vs 24.8x) | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.29 vs ARDT's 1.40 | |
| Dividends | 0.7% yield; 5-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs ARDT's -30.5% | |
| Efficiency (ROA) | 11.3% ROA vs DBVT's -89.0% |
ARDT vs DBVT vs HCA vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ARDT vs DBVT vs HCA vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
HCA leads 2 • ARDT leads 1 • DBVT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA and DBVT operate at a comparable scale, with $75.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ARDT's 2.1%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $6.4B | $0 | $75.6B | $1.6B |
| EBITDAEarnings before interest/tax | $733M | -$112M | $15.5B | $212M |
| Net IncomeAfter-tax profit | $134M | -$168M | $6.8B | $153M |
| Free Cash FlowCash after capex | $214M | -$151M | $7.7B | $392M |
| Gross MarginGross profit ÷ Revenue | +60.5% | — | +41.5% | +65.4% |
| Operating MarginEBIT ÷ Revenue | +8.9% | — | +15.8% | +12.3% |
| Net MarginNet income ÷ Revenue | +2.1% | — | +9.0% | +9.8% |
| FCF MarginFCF ÷ Revenue | +3.3% | — | +10.2% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.0% | — | +6.7% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +91.5% | +44.6% | -4.1% |
Valuation Metrics
ARDT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 10.3x trailing earnings, ARDT trades at a 58% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, ARDT's 6.2x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.4B | $1712.35T | $95.9B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $1712.35T | $145.1B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | 10.29x | -0.76x | 15.12x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.65x | — | 14.19x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.72x | — |
| EV / EBITDAEnterprise value multiple | 6.17x | — | 9.37x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 0.22x | — | 1.27x | 4.00x |
| Price / BookPrice ÷ Book value/share | 0.83x | 0.66x | — | 3.28x |
| Price / FCFMarket cap ÷ FCF | 5.47x | — | 12.47x | 12.28x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDT's 1.34x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.0% | -130.2% | — | +8.8% |
| ROA (TTM)Return on assets | +2.6% | -89.0% | +11.3% | +5.4% |
| ROICReturn on invested capital | +7.5% | — | +19.9% | +18.9% |
| ROCEReturn on capital employed | +7.9% | -145.7% | +27.0% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 1.34x | 0.13x | — | 0.04x |
| Net DebtTotal debt minus cash | $1.6B | -$172M | $49.2B | -$1.0B |
| Cash & Equiv.Liquid assets | $710M | $194M | $1.0B | $1.1B |
| Total DebtShort + long-term debt | $2.3B | $22M | $50.2B | $70M |
| Interest CoverageEBIT ÷ Interest expense | 6.36x | -189.82x | 5.37x | 32.30x |
Total Returns (Dividends Reinvested)
HCA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HCA five years ago would be worth $20,974 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ARDT's -30.5%. The 3-year compound annual growth rate (CAGR) favors HCA at 16.3% vs ARDT's -15.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.4% | +4.9% | -8.6% | +25.3% |
| 1-Year ReturnPast 12 months | -30.5% | +110.4% | +19.7% | +16.5% |
| 3-Year ReturnCumulative with dividends | -38.5% | +19.7% | +57.4% | +14.5% |
| 5-Year ReturnCumulative with dividends | -38.5% | -69.1% | +109.7% | +60.9% |
| 10-Year ReturnCumulative with dividends | -38.5% | -87.0% | +450.5% | -11.0% |
| CAGR (3Y)Annualised 3-year return | -15.0% | +6.2% | +16.3% | +4.6% |
Risk & Volatility
Evenly matched — HCA and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than ARDT's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs ARDT's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 1.26x | 0.29x | 1.06x |
| 52-Week HighHighest price in past year | $15.48 | $26.18 | $556.52 | $36.60 |
| 52-Week LowLowest price in past year | $8.07 | $7.53 | $330.00 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +76.3% | +77.1% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 48.1 | 30.8 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 382K | 252K | 1000K | 2.3M |
Analyst Outlook
HCA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ARDT as "Buy", DBVT as "Buy", HCA as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.9% for HCA (target: $527). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $13.33 | $46.33 | $527.45 | $44.00 |
| # AnalystsCovering analysts | 12 | 15 | 46 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | — | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +10.5% | +0.5% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCA leads in 2 (Total Returns, Analyst Outlook). 1 tied.
ARDT vs DBVT vs HCA vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ARDT or DBVT or HCA or ALKS a better buy right now?
For growth investors, HCA Healthcare, Inc.
(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Ardent Health Partners, LLC (ARDT) offers the better valuation at 10. 3x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Ardent Health Partners, LLC (ARDT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARDT or DBVT or HCA or ALKS?
On trailing P/E, Ardent Health Partners, LLC (ARDT) is the cheapest at 10.
3x versus Alkermes plc at 24. 8x. On forward P/E, Ardent Health Partners, LLC is actually cheaper at 8. 7x.
03Which is the better long-term investment — ARDT or DBVT or HCA or ALKS?
Over the past 5 years, HCA Healthcare, Inc.
(HCA) delivered a total return of +109. 7%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HCA returned +450. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARDT or DBVT or HCA or ALKS?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Ardent Health Partners, LLC's 1. 40β — meaning ARDT is approximately 389% more volatile than HCA relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 134% for Ardent Health Partners, LLC — giving it more financial flexibility in a downturn.
05Which is growing faster — ARDT or DBVT or HCA or ALKS?
By revenue growth (latest reported year), HCA Healthcare, Inc.
(HCA) is pulling ahead at 7. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: HCA Healthcare, Inc. grew EPS 29. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARDT or DBVT or HCA or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ARDT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARDT or DBVT or HCA or ALKS more undervalued right now?
On forward earnings alone, Ardent Health Partners, LLC (ARDT) trades at 8.
7x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — ARDT or DBVT or HCA or ALKS?
In this comparison, HCA (0.
7% yield) pays a dividend. ARDT, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is ARDT or DBVT or HCA or ALKS better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, ARDT: -38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARDT and DBVT and HCA and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ARDT is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; HCA is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock. HCA pays a dividend while ARDT, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.